DFE Pharma to Launch New Biopharma Excipient Solution
DFE’s new line will offer market purity and low endotoxin excipients for use in formulation, while providing drug developers and manufacturers high-quality excipient technology and services.
DFE Pharma, a pharmaceutical excipient solutions company located in Germany, announced on April 21, 2021 that it has launched BioHale, a new product line aimed at addressing worldwide supply challenges for biopharmaceutical companies.
According to a company press release, the new line will offer market purity and low endotoxin excipients for use in formulation, while providing drug developers and manufacturers with high quality excipient technology and services to advance therapeutic formulation.
“As a trusted solution provider and development partner to leading pharma brands, we are committed now to supporting customers in the formulation process for efficacious delivery of biologics,” said Bas van Driel, CEO of DFE Pharma, in the press release. “With the high purity and low endotoxin quality of BioHale excipients, combined with increased security of supply and stringent control over relevant supply chain processes, we can meet, if not exceed, the growing demands of new biopharma customers, as well as existing customers.”
Source: DFE
